Xin Lang Cai Jing·2026-03-27 06:53Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a cumulative increase of 6.82% over three consecutive days [1][4]. Company Overview - Hangzhou Tiger Medical Technology Co., Ltd. was established on December 15, 2004, and went public on August 17, 2012. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business activities include I-IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - The Guotai Haitong Innovation Medicine Mixed Fund A (014157) holds 103,000 shares of Tiger Med, representing 5.42% of the fund's net value, making it the second-largest holding [2][5]. - The fund has reported a floating profit of approximately 261,600 CNY today and a total floating profit of 333,700 CNY during the three-day increase [2][5]. - The fund was established on December 23, 2021, with a current size of 55.78 million CNY. Year-to-date, it has incurred a loss of 8.96%, ranking 8264 out of 8898 in its category, and has a one-year return of 0.3%, ranking 7499 out of 8181 [2][5]. Fund Manager Performance - The fund manager, Li Zibo, has been in position for 4 years and 96 days, managing a total asset size of 2.66 billion CNY. The best fund return during his tenure is 44.86%, while the worst return is -18.64% [3][7].